Zomedica Corp. 2025 Annual Report: Critical Developments and Investor Insights

Introduction

Zomedica Corp., a company focused on the development and commercialization of products for companion animals, has released its Form 10-K annual report for the fiscal year ended December 31, 2025. This comprehensive document provides critical disclosures and developments that current and prospective investors should carefully consider.

Key Highlights from the 2025 Annual Report

• Delisting from NYSE American and Transition to OTCQB:
  • On March 4, 2025, Zomedica Corp. was notified by NYSE American that its common shares would be suspended from trading and delisted due to noncompliance with Section 1003(f)(v), which relates to trading at a low price per share over a substantial period.
  • The company subsequently received approval for its common shares to be quoted on the OTC Markets’ OTCQB market tier, an electronic quotation service operated by OTC Markets Group Inc. for eligible securities traded over-the-counter.
  • This transition is significant for investors, as trading on OTCQB typically involves less liquidity and potentially higher volatility, which may affect share price and investor access.
• Public Float and Shares Outstanding:
  • As of June 30, 2025, Zomedica’s aggregate market value of common shares held by non-affiliates was approximately \$38.3 million, based on the last reported sale price on the OTCQB.
  • As of March 16, 2026, the number of common shares outstanding was 979,949,668.
• Issuer Status and Filing Compliance:
  • Zomedica is classified as a non-accelerated filer and a smaller reporting company, not an emerging growth company.
  • The company confirmed that it had filed all required reports and submitted all required Interactive Data Files pursuant to SEC regulations.
• No Recent Financial Restatements or Shell Company Status:
  • The report confirms that Zomedica is not a shell company.
  • There have been no financial restatements or error corrections requiring recovery analysis for incentive-based compensation.
• Risk Factors and Forward-Looking Statements:
  • The company draws attention to the “Risk Factors” section (Item 1A), emphasizing exposure to adverse macroeconomic conditions, regulatory changes, and other uncertainties that may materially impact its results and share price.
  • Forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from expectations.
• Business Developments:
  • Zomedica has acquired a significant patent portfolio and expanded its marketing and social media programs.

Potentially Price-Sensitive Information for Shareholders

• Delisting from NYSE American: The delisting is a material event that may reduce institutional investor interest, increase share price volatility, and affect liquidity. Transitioning to the OTCQB is generally seen as a downgrade and could have a negative impact on the company’s market perception.
• Share Structure and Float: The relatively high number of shares outstanding and the modest public float value may affect the potential for volatility and dilution. Investors should monitor any future financings or changes to the share structure.
• Compliance Status: The company’s compliance with SEC reporting requirements is positive, but the characterization as a non-accelerated, smaller reporting company means reduced reporting obligations and potentially fewer resources for rapid growth.
• Risk Disclosures: The company’s explicit reference to substantial risks, including those in the “Risk Factors” section, suggests ongoing and significant uncertainties that could impact share value.
• Strategic Actions: While Zomedica has made strategic moves to acquire intellectual property and enhance marketing, no transformative product launches, partnerships, or financial performance milestones are disclosed in the provided excerpt.

Conclusion

For investors: The most newsworthy and potentially share price-moving item in this annual report is Zomedica’s delisting from the NYSE American and the subsequent shift to OTCQB. This change may reduce visibility, liquidity, and institutional participation, thereby potentially impacting share price. The company’s substantial share count and modest float, along with its compliance as a smaller reporting company, mean that risk and volatility may continue to be elevated. No major new product or partnership announcements are disclosed in this section of the report.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review the full annual report and consult with their financial advisors before making any investment decisions. All forward-looking statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied herein.

View Zomedica Corp. Historical chart here